Global Ganja Report

A judge for the US District Court for the Southern District of New York on Feb. 26 dismissed a lawsuit challenging the Schedule I classification for cannabis under the Controlled Substances Act. Judge Alvin Hellerstein granted the government's motion to dismiss because the plaintiffs failed to exhaust all administrative remedies prior to initiating the suit. The "exhaustion rule" requires "that parties exhaust prescribed administrative remedies before seeking relief from federal courts."

Medical marijuana advocates and bureaucrats from regulatory agencies around the world have both been awaiting a statement on the risks and benefits of cannabidiol (CBD) from the World Health Organization's Expert Committee on Drug Dependence (ECDD). Now the assessment on the non-psychoactive cannabinoid is in, and it is encouraging news for those who have been hoping for its removal from Schedule 1, the international designation for drugs with no therapeutic value but high potential for abuse.

It has been a year and counting since Ohio passed its medical marijuana law in June 2016, and nobody has yet received any cannabis under the program. The logjam is due to the failure of the state to issue licenses to any cultivators, processors, dispensaries or testing labs.

Finally, the first sign of progress is seen as a local technical college has come forward to offer cannabis testing services.

Amid the legal ambiguities about the status of cannabidiol (CBD), authorities in one state that had cracked down on preparations of the salutary cannabinoid are now admitting that they themselves are confused. Weeks after Indiana State Excise Police declared products containing CBD oil to be illegal—and carrying out a raid on an Indianapolis-aread natural goods store to prove it—state officials say they don’t actually know if CBD oil products are illegal or not.

It has been a long, slow ride for patients hoping to get access to medical marijuana in the Lone Star state—and then just special strains of low-THC cannabis, and only for those suffering from "intractable epilepsy." Three dispensaries are hoping to get final approval from Texas authorities to start cultivating next month. Of course, it will be several more months before they can actually begin distributing—and then ambiguities in the law may mean further delays. Activists and lawmakers are pushing both to clear things up and expand the scope of the program.

Hemp Business Journal reports that products infused with CBD oil are leading growth in hermp-derived products sold in the United States generally, which in 2016 had a collective retail value of $688 million. This figure represents a five year 22% compound annual growth rate (CAGR). Joining more traditional products such as shelled seed, protein powder, soaps and lotions, are growing lines of medicinal preparations such as CBD edibles. Hemp-derived cannabidiol (CBD) accounted for $130 million in sales last year.

Oops, he did it again. Acting Drug Enforcement Administration chief Chuck Rosenberg reiterated his oft-voiced opinion on May 25 that "marijuana is not medicine." The Washington Examiner reports that he told an audience at a clinic in Cleveland: "If it turns out that there is something in smoked marijuana that helps people, that's awesome. I will be the last person to stand in the way of that... But let's run it through the Food and Drug Administration process, and let's stick to the science on it."

Here's some counterintuitive news for those who have been hammered all their lives with claims that cannabis causes memory loss. A new study by scientists at the University of Bonn, written up in the journal Nature Medicine, finds that aging mice treated with daily small doses of THC actually experienced a reversal of cognitive decline. That is, they started doing better on cognitive tasks, such as going though a maze. The researchers foresee potential cannabis-based treatment to fend off dementia. "If we can rejuvenate the brain so that everybody gets five to 10 more years without needing extra care then that is more than we could have imagined," said study leader Andras Bilkei-Gorzo.